Monteris Medical

Monteris Medical Inc. (MMI) is developing a revolutionary medical device to treat solid-tissue tumours without the significant costs, dangers, and long recovery periods associated with current treatments. The first application of the technology is for the treatment of brain tumours.

The Product

The company’s lead product (AutoLITT) has the potential to fundamentally change the way defined, solid tissue tumours are treated. The device uses MRI–sourced data to guide a laser probe to the site of the tumour. Once there, the probe delivers laser energy to coagulate (heat and kill) the tumour with minimal damage to surrounding normal tissues. The therapeutic process is monitored in real time during treatment. The components of the AutoLITT product have been created and tested at the alpha stage in a variety of mediums.

The Potential

Current treatments for reducing solid tissue tumours involve expensive and invasive interventions including surgery, chemotherapy and radiation therapy. The AutoLITT system has several advantages over conventional therapies, including:

  • Enhanced outcome potential with minimal invasiveness and relatively benign cosmetic effects.
  • Lower acquisition, operating and post-treatment costs.
  • Potential to be performed on an outpatient basis.

2003 Milestones

In January 2003, the company changed its name from AutoLITT to Monteris Medical. In May, MMI closed on the first tranche ($5.2 million) of a $7.2 million Series A financing.

The year 2003 saw significant growth in the company, with staffing levels increasing from 4 to 12 people. There are currently 17 staff members at Monteris.

The Future

Having received guidance from the FDA on the information required to complete its 510(k) application, MMI is now in a position to push ahead rapidly with development of the AutoLITT system.

Monteris conducted in vivo studies of the AutoLITT System in five live swine in October 2005. The objectives of the trial were to demonstrate system effectiveness, to determine optimum laser parameters, and to identify any remaining engineering requirements. The trial was very successful, with system performance, effectiveness, and safety results demonstrated.

Monteris Medical is planning pre-clinical trials for the spring of 2007 and clinical trials, on human patients, for the winter of 2007.

For more information, contact:

Dr. Mark Torchia
Chief Scientific Officer, Monteris Medical
Email. mtorchia@monteris.com